TRPM8 agonist demonstrates rapid improvement in dry eye disease
WASHINGTON — A TRPM8 agonist demonstrated early onset of action in the treatment of signs and symptoms of dry eye disease, according to a study. David L. Wirta, MD, presented data from the COMET-1 study, which explored the safety and efficacy of AR-15512 (Aerie Pharmaceuticals), at the American Society of Cataract and Refractive Surgery meeting.